Compare DexCom, Inc. (DXCM) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Stryker Corporation — how do they compare? DexCom, Inc. trades at $77.41 (market cap $28.06B), while Stryker Corporation trades at $329.65 (market cap $121.31B). The key difference: Stryker Corporation is far larger — about 4.3× DexCom, Inc.'s market cap, and Stryker Corporation pays a 1.11% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | SYK | |
|---|---|---|
Market Cap | $28.06B | $121.31B |
Sector | Health | Technology |
52-Week High | $89.53 | $403.53 |
52-Week Low | $54.84 | $282.58 |
Enterprise Value | $27.03B | $133.07B |
Dividend Yield | — | 1.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Stryker (SYK) trades at $330.48, up 6.19% with strong analyst support (74% buy ratings) and a $388.44 consensus price target. The stock shows bearish technical signals despite recent earnings beats in Q3 and Q4 2025, offset by a Q1 2026 miss attributed to a temporary cyber disruption. Fundamentals remain solid with 63.83% gross margins and 13.21% net income margin, while the company continues innovation with Mako robotics expansion and new product launches.
The outlook remains positive given maintained full-year guidance and healthy end-market demand. Key risks include cybersecurity vulnerabilities and competitive pressures, but institutional confidence is high with no sell ratings. The current valuation at 36.63 P/E offers potential upside to the price target, supported by robust cash flow generation and dividend consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
